NEW YORK (GenomeWeb) – Vermillion reported after the close of the market on Monday a 47 percent decline in first quarter revenues

For the three months ended March 31, the Austin, Texas-based cancer diagnostics firm said that total revenues fell to $505,000 from $951,000 in the year-ago quarter.

Product revenues were $505,000, down from $635,000 in Q1 2015. As Vermillion noted, product revenue in Q1 2015 included the one-time recognition of $163,000 in deferred product revenue upon the signing of its commercial agreement with Quest Diagnostics in March 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.